Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|May 15, 2020
- Pharmaceutical Technology-05-15-2020
- Volume 2020 eBook
- Issue 2
On Point: Biologics Drive Growth in Pre-Filled Syringes
Author(s)Felicity Thomas
As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.
Advertisement
With an aging population, the resultant increase in prevalence of chronic diseases, and more demand from patients for dosing convenience, the biopharma industry has seen an exponential increase in adoption of biological therapies delivered in prefilled syringes. The overall prefilled syringes market is forecasted to be worth nearly $10 billion by the year 2025, according to market research (1), driven in part by the rise in use of biological drugs. This article discusses the challenges, safety considerations, and emerging trends in the field of pre-filled syringes for biologics.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2020
May 2020
Pages: 20–23
Citation
When referring to this article, please cite it as F. Thomas, "On Point: Biologics Drive Growth in Pre-Filled Syringes," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).
Articles in this issue
over 6 years ago
Instrumenting Single-Use Processesover 6 years ago
Considerations in Contamination Controlover 6 years ago
Best systems and equipment for contamination controlover 6 years ago
Building Data Quality In Generates Quality Data Outover 6 years ago
Detecting Contamination in Cell Therapiesover 6 years ago
Optimizing Viral Vector Manufacturing for Gene Therapyover 6 years ago
Minimizing Contamination During Biopharma R&Dover 6 years ago
Complications in Process Simulation ExecutionAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Advertisement
Advertisement